Exploring the evolution of animal models for gout and hyperuricemia: A bibliometric analysis

doi:10.5246/jcps.2024.11.076

Journal of Chinese Pharmaceutical Sciences ›› 2024, Vol. 33 ›› Issue (11): 1058-1067.DOI: 10.5246/jcps.2024.11.076

• Original articles • Previous Articles Next Articles

Exploring the evolution of animal models for gout and hyperuricemia: A bibliometric analysis

Zining Peng¹^,²^,^#, Qian Deng²^,^#, Fanyu Meng¹^,²^,^#, Xingqiang Wang³, Nian Liu²^,^*(), Weitian Yan³^,^*(), Jiangyun Peng³^,^*()

¹ Department of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, Guandong, China
² Department of Geriatrics, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, Guandong, China
³ Department of Geriatrics, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, Guandong, China

Received:2024-04-21 Revised:2024-05-11 Accepted:2024-06-21 Online:2024-12-10 Published:2024-12-10
Contact: Nian Liu, Weitian Yan, Jiangyun Peng
About author:
^# Zining Peng, Qian Deng and Fanyu Meng contributed equally to this work.
Supported by:
The National Natural Science Foundation of China (Grant No. 82160901), Special Project for Social Development under the Key Research and Development Plan of the Yunnan Provincial Science and Technology Department (Grant No. 202403AC100019) and supported by Yunnan Key Laboratory of Dai and Yi Medicines (Yunnan University of Chinese Medicine) (Grant No. 2024SS24032).

Abstract

Abstract:

This study aimed to systematically analyze the research status and trends in animal models for gout and hyperuricemia (HUA) through a bibliometric approach. We retrieved relevant literature on animal models of gout and HUA from the Web of Science (WOS) database. Utilizing analysis software such as Citespace and VOSviewer, we conducted a comprehensive examination of annual publication trends, contributing countries, institutions, and authors. Our analysis revealed a steady increase in the number of publications in this field. China emerged as the leading country, with 113 publications. Zhen Liu was identified as the most influential author, while Nanjing University stood out as the most influential institution. Keyword analysis elucidated current focal points, uncovering evolving patterns and emerging hotspots within the research landscape. Current research predominantly centered on understanding the pathogenesis and exploring new treatment modalities for gout and HUA. This study offered valuable insights into research trends and hotspots related to animal models for gout and HUA, enabling researchers to stay informed about the latest developments in this field.

Key words: Animal model, Gout, Hyperuricemia, Bibliometric analysis

Supporting:

Zining Peng, Qian Deng, Fanyu Meng, Xingqiang Wang, Nian Liu, Weitian Yan, Jiangyun Peng. Exploring the evolution of animal models for gout and hyperuricemia: A bibliometric analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1058-1067.

Figures/Tables 7

References 15

[1]	Dalbeth, N.; Gosling, A.L.; Gaffo, A.; Abhishek, A. Gout. Lancet. 2021, 10287, 1843–1855.
[2]	Hansildaar, R.; Vedder, D.; Baniaamam, M.; Tausche, A.K.; Gerritsen, M.; Nurmohamed, M.T. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021, 3, e58–e70.
[3]	Safiri, S.; Kolahi, A.A.; Cross, M.; Hill, C.; Smith, E.; Carson-Chahhoud, K.; Mansournia, M.A.; Almasi-Hashiani, A.; Ashrafi-Asgarabad, A.; Kaufman, J.; Sepidarkish, M.; Shakouri, S.K.; Hoy, D.; Woolf, A.D.; March, L.; Collins, G.; Buchbinder, R. Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990-2017. Arthritis Rheumatol. 2021, 73, 702–714.
[4]	Li, L.J.; Zhang, Y.P.; Zeng, C.C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am. J. Transl. Res. 2020, 12, 3167–3181.
[5]	Chowalloor, P.V.; Keen, H.I. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann. Rheum. Dis. 2013, 72, 638–645.
[6]	Zhang, Y.Y.; Zhang, P.P.; Ding, H.X.; Zhang, X.; Liu, Y. HH-A, a honokiol derivative, alleviates hypoxic brain injury in the animal ischemic model by interacting with hemoglobin. J. Chin. Pharm. Sci. 2024, 33, 98.
[7]	McGrath, J.C.; Drummond, G.B.; McLachlan, E.M.; Kilkenny, C.; Wainwright, C.L. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160, 1573–1576.
[8]	Li, F.C.; Zhang, D.; Li, Z.; Hou, Z.M.; Chen, W.; Chen, J.; Hu, Y.Q. Exploring the landscape of stem cell research for Alzheimer’s disease: a bibliometric analysis spanning 2002–2021. J. Chin. Pharm. Sci. 2023, 32, 813.
[9]	Yu, K.; Hao, L.; Bu, F.; Guo, Y.; Duan, Y.; Hu, R. Knowledge structure and emerging trends of cognitive impairment induced by sleep deprivation: a bibliometric analysis based on CiteSpace and VOSviewer from 2000 to 2022: Erratum. Medicine. 2024, 103, e37557.
[10]	Ellegaard, O.; Wallin, J.A. The bibliometric analysis of scholarly production: How great is the impact? Scientometrics. 2015, 105, 1809–1831.
[11]	Lu, J.; Hou, X.; Yuan, X.; Cui, L.L.; Liu, Z.; Li, X.D.; Ma, L.D.; Cheng, X.Y.; Xin, Y.; Wang, C.; Zhang, K.K.; Wang, X.F.; Ren, W.; Sun, R.X.; Jia, Z.T.; Tian, Z.B.; Mi, Q.S.; Li, C.G. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 2018, 93, 69–80.
[12]	Lu, J.; He, Y.W.; Cui, L.L.; Xing, X.M.; Liu, Z.; Li, X.D.; Zhang, H.; Li, H.L.; Sun, W.Y.; Ji, A.C.; Wang, Y.; Yin, H.Y.; Li, C.G. Hyperuricemia predisposes to the onset of diabetes via promoting pancreatic β-cell death in uricase-deficient male mice. Diabetes. 2020, 69, 1149–1163.
[13]	Li, D.L.; Yuan, S.Y.; Deng, Y.Y.; Wang, X.W.; Wu, S.H.; Chen, X.S.; Li, Y.M.; Ouyang, J.T.; Lin, D.Y.; Quan, H.H.; Fu, X.W.; Li, C.; Mao, W. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Front. Immunol. 2023, 14, 1282890.
[14]	Liang, J.H.; Yi, X.L.; Gong, J.M.; Du, Z. Evaluation of the inhibitory effects of antigout drugs on human carboxylesterases in vitro. Toxicol. Vitro. 2024, 98, 105833.
[15]	Yokose, C.; Challener, G.; Jiang, B.H.; Zhou, B.J.; McCormick, N.; Tanikella, S.; Panchot, K.M.Q.; Kohler, M.J.; Yinh, J.; Zhang, Y.Q.; Bates, D.W.; Januzzi, J.L.; Sise, M.; Wexler, D.; Choi, H.K. Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: a comparative effectiveness analysis. Semin. Arthritis Rheum. 2024, 66, 152441.

Exploring the evolution of animal models for gout and hyperuricemia: A bibliometric analysis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 15

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Gong Fang, Wenxi Li. Advances in the treatment of hyperuricemia with traditional Chinese medicine [J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(5): 381-395.
[2]	Suqiong Huang, Jingyuan Wan, Tingting Du, Tao Gong, Jing Zhang, Xinhui Jiang. The relationship between the contents of 13 amino acids in brain tissues and the progression of NAFLD via C57BL/6 model mice [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 441-451.
[3]	Gong Fang, Wenxi Li, Jie Zhang, Qinghua Ke, Xinggui Zhu, Lihua Long, Changhai Li. Safety and tolerability of available drugs for hyperuricemia: a critical review and an update on recent developments [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 397-411.
[4]	Xin Jin^#, Ting-Ting Sun^#, Qi Wang, Huan Xu, Tie-Jun Wei, Qiu-Chen He, Li-He Zhang, De-Min Zhou^*. Interference RNA induction and drug target validation [J]. , 2009, 18(4): 293-301.
[5]	LIUXiao-yan, LI Feng-yun , CHI Zhi-hong, WANG Yin-ye^*. Protective Effects of Oral Fructose-1, 6-diphosphate on Liver Injury in Animal Models [J]. , 2006, 15(3): 188-193.